Payment overview · 2025
General Payments
$905.50
57 reported records · 13 companies
Healthcare provider profile · identity verified
Matthew D Mcclain, MD
Allopathic & Osteopathic Physicians|Family Medicine · HATTIESBURG, MS · NPI 1962517276
Verified facts
What the public records show
CMS Open Payments records show Matthew D Mcclain, MD received $905.50 in general payments during 2025 across 57 reported records.
ABBVIE INC. accounted for 32.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $294.17 | 32.5% | 22 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $120.96 | 13.4% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $74.47 | 8.2% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $66.23 | 7.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.31 | 6.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.05 | 5.9% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $52.30 | 5.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.71 | 5.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.27 | 4.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.48 | 3.6% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.45 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.96 | 2.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.14 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $905.50 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $192.00 | 13 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $99.84 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $86.93 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $66.23 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $57.61 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $57.61 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $55.31 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.85 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.85 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $52.30 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $52.20 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $51.71 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $40.27 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $40.13 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.45 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.45 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $9.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
102 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 716 | 189 |
| Amlodipine Besylate | Amlodipine Besylate | 606 | 166 |
| Hydrochlorothiazide | Hydrochlorothiazide | 542 | 148 |
| Atorvastatin Calcium | Atorvastatin Calcium | 507 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 343 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 304 | 79 |
| Tizanidine Hcl | Tizanidine Hcl | 268 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 253 | 69 |
| Famotidine | Famotidine | 225 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 225 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 216 | 57 |
| Potassium Chloride | Potassium Chloride | 195 | 59 |
| Baclofen | Baclofen | 190 | 69 |
| Gabapentin | Gabapentin | 165 | 44 |
| Montelukast Sodium | Montelukast Sodium | 160 | 49 |
| Carvedilol | Carvedilol | 158 | 38 |
| Lisinopril | Lisinopril | 155 | 41 |
| Furosemide | Furosemide | 152 | 52 |
| Metformin Hcl | Metformin Hcl | 130 | 37 |
| Meloxicam | Meloxicam | 124 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 115 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 48 |
| Allopurinol | Allopurinol | 103 | 28 |
| Synthroid | Levothyroxine Sodium | 102 | 18 |
| Trazodone Hcl | Trazodone Hcl | 99 | 34 |
| Azithromycin | Azithromycin | 97 | 72 |
| Omeprazole | Omeprazole | 97 | 26 |
| Fluconazole | Fluconazole | 94 | 42 |
| Sertraline Hcl | Sertraline Hcl | 93 | 29 |
| Bupropion Hcl Sr | Bupropion Hcl | 92 | 18 |
| Buspirone Hcl | Buspirone Hcl | 92 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 18 |
| Glimepiride | Glimepiride | 80 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 16 |
| Alprazolam | Alprazolam | 62 | 21 |
| Meclizine Hcl | Meclizine Hcl | 61 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 41 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | 19 |
| Mupirocin | Mupirocin | 56 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 24 |
| Alendronate Sodium | Alendronate Sodium | 53 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 20 |
| Tramadol Hcl | Tramadol Hcl | 53 | 19 |
| Valacyclovir | Valacyclovir Hcl | 51 | 17 |
| Valsartan | Valsartan | 49 | 16 |
| Fenofibrate | Fenofibrate | 43 | suppressed |
| Prednisone | Prednisone | 43 | 39 |
| Simvastatin | Simvastatin | 43 | suppressed |
| Klor-Con 10 | Potassium Chloride | 42 | 12 |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 27 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 17 |
| Cefuroxime | Cefuroxime Axetil | 32 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Cefdinir | Cefdinir | 23 | 22 |
| Colchicine | Colchicine | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $905.50 · 57 records | ABBVIE INC. | ABRYSVO, BOTOX, CAPVAXIVE, COMIRNATY, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, INSPIRE, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error